Citations

Clear

2511 citation(s) found for "Yang, Mo".

Robust Principal Component Analysis with Wavelet-Based Sparsity Promotion to Mitigate Reverberation Clutters for Ultrasound Attenuation Estimation
Lok, U‐Wai , Tang, Shanshan , Zhou, Chenyun , Watt, Kymberly D., Callstrom, Matthew R. , Trzasko, Joshua D. , Chen, Shigao , Lok, U-Wai , Gong, Ping , Huang, Chengwu , Yang, Lulu

Mayo Clinic

2022 IEEE International Ultrasonics Symposium (IUS) | December 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ius54386.2022.9957606 Get It

Facial Nerve Schwannoma Treatment with Stereotactic Radiosurgery (SRS) versus Resection followed by SRS: Outcomes and a Management Protocol
Dayawansa, Sam , Mantziaris, Georgios , Mehta, Gautam U. , Leković, Gregory P. , Mathieu, David , Reda, Wael A. , Lee, Cheng-chia, Barnet, Gene, Lunsford, L. Dade , Sheehan, Jason P. , Mehta, Gautam U , Mathieu, David , Trifiletti, Daniel M , Mantziaris, Georgios , Dumot, Chloé , Kondziolka, Douglas , Reda, Wael A. , Liščák, Roman , Kaufmann, Anthony M. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 1, 2022 | Volume: 85 | Issue: 01 | Pages: 075-080

10.1055/a-1990-2861 | PMID 38274481 Get It

Abstract Background Stereotactic radiosurgery (SRS) and resection are treatment options for patients with facial nerve schwannomas without mass effect. Objective This article evaluates outcomes of patients treated with SRS versus resection + SRS. Method We retrospectively compared 43 patients treated with SRS to 12 patients treated with resection + SRS. The primary study outcome was unfavorable combined endpoint, defined as worsening or new clinical symptoms, and/or tumor radiological progression. SRS (38.81 ± 5.3) and resection + SRS (67.14 ± 11.8) groups had similar clinical follow-ups. Results At the time of SRS, the tumor volumes of SRS (mean ± standard error; 1.83 ± 0.35 mL) and resection + SRS (2.51 ± 0.75 mL) groups were similar. SRS (12.15 ± 0.08 Gy) and resection + SRS (12.16 ± 0.14 Gy) groups received similar radiation doses. SRS group (42/43, 98%) had better local tumor control than the resection + SRS group (10/12, 83%, p = 0.04). Most of SRS (32/43, 74%) and resection + SRS (10/12, 83%) group patients reached a favorable combined endpoint following SRS (p = 0.52). Considering surgical associated side effects, only 2/10 patients of the resection + SRS group reached a favorable endpoint (p < 0.001).Patients of SRS group, who are > 34 years old (p = 0.02), have larger tumors (> 4 mL, 0.04), internal auditory canal (IAC) segment tumor involvement (p = 0.01) were more likely to reach an unfavorable endpoint. Resection + SRS group patients did not show such a difference. Conclusion While resection is still needed for larger tumors, SRS offers better clinical and radiological outcomes compared to resection followed by SRS for facial schwannomas. Younger age, smaller tumors, and non-IAC situated tumors are factors that portend a favorable outcome.
Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis
Li, Yawei , Xin, Wu , Yang, Ping , Jiang, Guoqian , Luo, Yuan , Yang, Ping , Luo, Yuan

Mayo Clinic

Genomics, Proteomics & Bioinformatics | November 30, 2022 | Volume: 20 | Issue: 5 | Pages: 850-866

10.1016/j.gpb.2022.11.003 | PMID 36462630 Get It

Abstract The recent development of imaging and sequencing technologies enables systematic advances in the clinical study of lung cancer. Meanwhile, the human mind is limited in effectively handling and fully utilizing the accumulation of such enormous amounts of data. Machine learning-based approaches play a critical role in integrating and analyzing these large and complex datasets, which have extensively characterized lung cancer through the use of different perspectives from these accrued data. In this review, we provide an overview of machine learning-based approaches that strengthen the varying aspects of lung cancer diagnosis and therapy, including early detection, auxiliary diagnosis, prognosis prediction, and immunotherapy practice. Moreover, we highlight the challenges and opportunities for future applications of machine learning in lung cancer.
Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
Bhardwaj, Vaishali , Jalali, Shahrzad , Tang, Xinyi , Mukherjee, Prithviraj , Kim, Hyo-Jin, Mudappathi, Rekha , Wenzl, Kerstin , Novak, Anne J. , Ansell, Stephen M. , Bhardwaj, Vaishali , Villasboas, José C. , Yang, Zhi-Zhang , Mondello, Patrizia , Wang, Junwen , Krull, Jordan E.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2904-2905

10.1182/blood-2022-166450 Get It

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
Parekh, Samir , Yang, David T. , Kostakoğlu, Lale , Baghdadi, Tareq Al, Maddocks, Kami J. , Romer, Mark D., Inwards, David J. , Lerner, Rachel E. , Little, Richard F. , Friedberg, Jonathan W. , Leonard, John P. , Parekh, Samir , Smith, Mitchell R. , Jegede, Opeyemi A. , Martin, Peter, Till, Brian G. , Casulo, Carla , Bartlett, Nancy L. , Caimi, Paolo F. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 186-188

10.1182/blood-2022-170381 Get It

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma
Jin, Fengyan, Yang, Pei‐Yu , Chen, Haimin , Liang, Xinyue , Xu, Weiling , Yu, Shanshan , Yi, Xingchen, Tian, Mengru, Yue, Tingting , Yan, Yurong, Hu, Zhongli, Kumar, Shaji , Zhou, Fan , Jin, Fengyan , Huang, Wenyang , Guo, Qiang , Yue, Tingting, Li, Mengyao , Zhang, Yingjie , Zhang, Mengxue , Dai, Yun

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4360-4361

10.1182/blood-2022-168602 Get It

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma
Liu, Xiaobo , Yang, Ting , Kumar, Shaji , Jin, Fengyan, Dai, Yun , Jin, Fengyan

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4185-4186

10.1182/blood-2022-168239 Get It